Strategic Partnerships Onco360 has a strong track record of partnering with leading pharmaceutical companies (Astellas, Syndax, Rigel, Komzifti, Revuforj) and recently secured collaborations with Takeda, highlighting ongoing opportunities to expand co-developed or preferred pharmacy arrangements with major innovators.

Therapy Portfolio Expansion The company serves oncology and rare disease patients and has recently joined as a national specialty pharmacy partner for multiple high-profile therapies (VEPPANU, VORANIGO, Revuforj, Komzifti), signaling continued potential to broaden access across additional oncology indications and targeted treatments.

National Reach With national dispensing capabilities through accredited oncology pharmacies and a sizable revenue base, Onco360 can be a preferred partner for manufacturers seeking scalable distribution, patient access programs, and consistent specialty pharmacy fulfillment nationwide.

Patient Support Fo cus The emphasis on comprehensive patient support programs, adherence management, and clinical expertise positions Onco360 as a strategic collaborator for manufacturers aiming to optimize real-world outcomes, adherence metrics, and supportive services bundled with launches.

Growth and Scale A mid-to-large employer base (501-1000) and revenue in the hundreds of millions suggest capacity for expanded service lines, expanded payer negotiations, and potential value-added services such as prior authorization management, specialty logistics, and data-driven patient engagement at scale.